Study to Investigate the Effect of Paroxetine Mediated CYP2D6 Inhibition on the Pharmacokinetics of Tamsulosin in Healthy Male Volunteers
NCT02264184 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24
Last updated 2014-10-15
Summary
Study to investigate the effect of CYP2D6 inhibition by paroxetine on the single oral dose pharmacokinetics of tamsulosin and to investigate the effect on safety and tolerability
Conditions
- Healthy
Interventions
- DRUG
-
Tamsulosin
- DRUG
-
Paroxetine
Sponsors & Collaborators
- lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- CROSSOVER
Eligibility
- Min Age
- 21 Years
- Max Age
- 50 Years
- Sex
- MALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2008-09-30
- Primary Completion
- 2008-12-31
More Related Trials
-
Safety Profile of Secotex ® in Patients With Benign Prostatic Hyperplasia
NCT02245529 ·Status: COMPLETED
-
A Study To Compare 3 Different Formulations Of Tamsulosin At Steady State.
NCT00609596 ·Status: COMPLETED ·Phase: PHASE1
-
Actual Use Study of Tamsulosin in Men
NCT02573311 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of Tamsulosin on PE Compared With Paroxetine Hydrochloride
NCT03879746 ·Status: UNKNOWN ·Phase: PHASE3
-
Long Term Study of Solifenacin Succinate and Tamsulosin Hydrochloride Oral Controlled Absorption System (OCAS) in Males With Lower Urinary Tract Symptoms
NCT01021332 ·Status: COMPLETED ·Phase: PHASE3
-
Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between Solifenacin and Tamsulosin
NCT02180997 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Tolerability and Efficacy of Tamsulosin 0.4mg OCAS Formulation in Patients Who Are Unsatisfied With the Treatment of Tamsulosin 0.2mg Conventional Formulation
NCT02180789 ·Status: COMPLETED ·Phase: PHASE4
-
Study to Evaluate the Clinical Efficacy and Safety of Tamsulosin Alone or in Combination With Solifenacin for the Treatment in Men With Lower Urinary Tract Symptoms Including Overactive Bladder Symptoms
NCT02715024 ·Status: COMPLETED ·Phase: PHASE4
-
EC905 Pharmacokinetic Profile Study
NCT02634489 ·Status: COMPLETED ·Phase: PHASE1
-
Bioavailability Study of Fixed Dose Combination (FDC) Dutasteride and Tamsulosin Hydrochloride (HCl) Relative to One Dutasteride and One Tamsulosin HCl Tablet in Healthy Male Subjects
NCT02509104 ·Status: COMPLETED ·Phase: PHASE1
-
Clinical Trial to Compare the Solifenacin/Tamsulosin Combination Therapy With Tamsulosin Monotherapy for LUTS Due to BPH
NCT02972268 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Longidaze in the Treatment of Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia
NCT06568718 ·Status: COMPLETED ·Phase: NA
-
Study to Evaluate the Therapeutic Action of Tamsulosin and Finasteride in Symptomatic Benign Prostatic Hyperplasia (BPH) Patients
NCT02244229 ·Status: COMPLETED ·Phase: PHASE4
-
Trial of the Safety and Efficacy of Ozarelix in Participants With Benign Prostatic Hyperplasia (BPH)
NCT00743184 ·Status: TERMINATED ·Phase: PHASE2
-
Tamsulosin Hydrochloride 0.4 mg Capsules Under Fasting Conditions
NCT01149746 ·Status: COMPLETED ·Phase: PHASE1
-
Comparative Bioavailability of Two Fixed Dose Combination (FDC) Formulations of Dutasteride and Tamsulosin Hydrochloride Relative to Co-administration of Dutasteride With Tamsulosin Hydrochloride in Healthy Male Subjects Under Fed and Fasted States
NCT02184585 ·Status: COMPLETED ·Phase: PHASE1
-
A Study With Combination Treatment (Tamsulosin Hydrochloride and Solifenacin Succinate) in Male Patients With LUTS/BPH
NCT00510406 ·Status: COMPLETED ·Phase: PHASE2
-
(Phosphodiesterase 5 Inhibitors & α-blockers): Single Versus Combined Therapy in Benign Prostatic Hyperplasia
NCT05236634 ·Status: UNKNOWN ·Phase: NA
-
A Phase 4 Study With Tamsulosin OCAS to Assess Nighttime Voiding.
NCT00379067 ·Status: COMPLETED ·Phase: PHASE4
-
Dutasteride and Flex Dose of Tamsulosin on as Needed Basis, to Treat Benign Prostatic Hyperplasia
NCT00701779 ·Status: COMPLETED ·Phase: PHASE4
-
Assess Safety & Efficacy of WC3055 in Men With Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia
NCT01939184 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Characterise the Effect of Tamsulosin on Lower Urinary Tract Symptoms (LUTS) and Detrusor Motor Activity in Patients Affected by Benign Prostatic Hyperplasia (BPH) and Storage Urinary Symptoms
NCT02245490 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With OAB Symptoms While Taking Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
NCT02757768 ·Status: COMPLETED ·Phase: PHASE4
-
An 8-week, Open-label, Uncontrolled Study of Tamsulosin 0.4mg in Men With Bothersome Urinary Symptoms
NCT01726270 ·Status: COMPLETED ·Phase: PHASE2
-
Cetrorelix Pamoate in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
NCT00663858 ·Status: COMPLETED ·Phase: PHASE3